On April 8, 2024 Alterome Therapeutics, Inc., a biopharmaceutical company pioneering the development of next generation, small molecule targeted therapies for the treatment of cancer, reported promising preclinical data from their lead pipeline candidate, ALTA-2618, a mutation-selective inhibitor for AKT1 E17K driven cancers (Press release, Alterome Therapeutics, APR 8, 2024, View Source [SID1234641916]). The data are being presented in a poster presentation on April 8th at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2024, taking place in San Diego, CA on April 5-10, 2024.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

ALTA-2618 is an orally bioavailable, mutant-selective, and covalent allosteric inhibitor of AKT1 E17K. AKT1 E17K is a clinically validated oncogene that drives cancers, including breast, endometrial, and prostate cancers. This program is designed for patients with limited treatment options and is expected to begin clinical testing in the next year.

"We’re excited to present data at AACR (Free AACR Whitepaper) featuring Alterome’s lead program, ALTA-2618, the first AKT1 E17K-selective inhibitor. We believe this data provides validation of the strong dependence of certain cancers on this mutation and underscores the high impact a selective inhibitor could achieve with continuous target coverage," said Eric Murphy, Ph.D., co-founder and CEO of Alterome Therapeutics. "This work was an important step forward in Alterome’s mission to discover precise therapies that generate preclinical tumor regressions with improved safety profiles, and supports the advancement of ALTA-2618 into first-in-human clinical trials in 2024."

Key Findings:

ALTA-2618 is the first allosteric & mutant-selective drug for AKT1 E17K driven cancers.
ALTA-2618 has favorable pharmacokinetic properties across multiple preclinical species.
ALTA-2618 is well tolerated with daily oral dosing in tumor-bearing mice.
The compound demonstrated significant anti-tumor effects in clinically-relevant PDX models driven by AKT1 E17K.
No on-target toxicities (e.g., hyperglycemia) are observed with daily ALTA-2618 treatment.
Poster Presentation Details:

Title: Discovery of ALTA-2618, the first allosteric, mutant-selective targeted therapy for AKT1 E17K driven cancers
Session Title: Late-Breaking Research: Experimental and Molecular Therapeutics 2
Date and Time: Monday, April 8 from 1:30 p.m. – 5:00 p.m. PT
Abstract Number: LB173 / 19
Speaker/Lead Author: Tim Sen Wang, Ph.D., Alterome Therapeutics